A Genomic-Clinicopathologic Nomogram for the Prediction of Lymph Node Invasion in Prostate Cancer

Table 1

The clinicopathological characteristics of primary patients in SMOTE-balanced training and validation sets.

	Number of patients (%)		value
Characteristic	SMOTE-balanced training set (n = 291)	SMOTE-balanced validation set (n = 135)
Age, years
Mean [median]	61.50 [62]	61.15 [62]	0.640^a
IQR	57–66	56–66
PSA level (most recent), ng/mL
Mean [median]	1.17 [0.10]	1.00 [0.10]	0.698^a
IQR	0.03–0.18	0.03–0.17
Clinical stage
cT1	93 (31.96)	44 (32.59)	0.294^b
cT2	104 (35.74)	55 (40.74)
cT3	30 (10.31)	19 (14.07)
cT4	1 (0.34)	0 (0)
NA	63 (21.65)	17 (12.59)
Pathologic stage
pT2	98 (33.68)	47 (34.81)	0.534^b
pT3	181 (62.20)	85 (62.96)
pT4	10 (3.44)	1 (0.74)
NA	2 (0.69)	2 (1.48)
Gleason grade
<7	17 (5.84)	7 (5.19)	0.739^b
= 7	140 (48.11)	69 (51.11)
>7	134 (46.05)	59 (43.70)
Surgical margin resection status
R0	178 (61.17)	89 (65.93)	0.283^b
R1	97 (33.33)	36 (26.67)
R2	2 (0.69)	2 (1.48)
NA	14 (4.81)	8 (5.93)
Number of dissected lymph nodes
Mean [median]	12.15 [10]	10.75 [9]	0.170^a
IQR	5–16	5–15
Number of positive lymph nodes
Mean [median]	0.51 [0]	0.35 [0]	0.279^a
IQR	0	0
N stage
N0	235 (80.76)	112 (38.49)	0.297^c
N1	56 (19.24)	23 (7.90)

IQR: interquartile range; NA: not available; PSA: prostate-specific antigen; SMOTE: synthetic minority oversampling technique; ^at-test; ^bMann–Whitney U test; ^cchi-square test.